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Microglia, the immune cells of the brain, play a major role in the maintenance
of brain homeostasis and constantly screen the brain environment to detect any
infection or damage. Once activated by a stimulus, microglial cells initiate an immune
response followed by the resolution of brain inflammation. A failure or deviation in the
housekeeping function of these guardian cells can lead to multiple diseases, including
brain cancer and neurodegenerative diseases such as Alzheimer’s disease (AD). A small
number of studies have investigated the causal relation of both diseases, thereby
revealing an inverse relationship where cancer patients have a reduced risk to develop
AD and vice versa. In this review, we aim to shed light on the role of microglia in the
fate to develop specifically glioma as one type of cancer or AD. We will examine the
common and/or opposing genetic predisposition as well as associated pathways of
these diseases to unravel a possible involvement of microglia in the occurrence of either
disease. Lastly, a set of guidelines will be proposed for future research and diagnostics
to clarify and improve the knowledge on the role of microglia in the decision toward one
pathology or another.
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INTRODUCTION
The central nervous system (CNS) can be affected at any stage in life by numerous neurological
disorders and neurodegenerative diseases. Microglia, as key innate immune cells of the CNS, are the
first responders and able to recognize an abundance of factors that could compromise the CNS. For
the protection of the brain, microglia can trigger a vigorous immune and inflammatory response
and therefore puts them at the center of neurological conditions (Biber et al., 2007; Wake et al.,
2009; Chen and Trapp, 2016). The responsiveness of microglia in various diseases has been studied
in great detail. Collectively, these studies revealed the high plasticity of microglia and associated
regulative processes evident by the acquisition of regionally distinct spatio-temporal phenotypes
throughout life as adaptation to their local environment (Shemer et al., 2015; Grabert et al., 2016;
Ayata et al., 2018; Cheray and Joseph, 2018; Hammond et al., 2019; Masuda et al., 2019; Stratoulias
et al., 2019). Overall, microglia phenotype is influenced by a variety of factors including ontogeny
(Ginhoux et al., 2010; Kierdorf et al., 2013; Matcovitch-Natan et al., 2016), sex (Guneykaya et al.,
2018; Villa et al., 2018; Hammond et al., 2019), location (de Haas et al., 2008; Grabert et al., 2016;
Frontiers in Cellular Neuroscience | www.frontiersin.org 1 November 2019 | Volume 13 | Article 522
fncel-13-00522 November 18, 2019 Time: 13:40 # 2
Cheray et al. Microglial Role: Glioma Versus AD
Masuda et al., 2019), disease (Bisht et al., 2016; Keren-Shaul et al.,
2017), and age (Grabert et al., 2016; Galatro et al., 2017). Aging
is a natural, yet highly complex process, in which every part of
an organism gradually declines. It is a devious and multi-layered
progression affecting both the gene and protein level (e.g., DNA
replication errors, epigenetic changes, protein misfolding) as well
as cellular biochemistry and bioenergetics, which overall leads
to an impairment of tissue homeostasis and function (López-
Otín et al., 2013). Glioma and AD share aging as a common risk
factor. In light of microglial plasticity, it is highly interesting that
a number of studies suggest an inverse correlation between AD
and cancer in general implying microglia may be set or contribute
to an environment, which does not allow to change direction.
Considering the vast advances made in microglia biology in
glioma and AD, very little is known about the involvement of
these immune sentinels to regulate or contribute to this intriguing
relation of developing one yet being protected from acquiring the
other pathology.
In this short review, we will depict the findings of the role
and functionality of microglia in primary brain tumors and AD.
Furthermore, we will provide a brief overview of longitudinal
studies describing the inverse relation of both diseases. We then
endeavor to discuss and elucidate in microglia reported risk genes
and associate pathways to establish a link and/or cause in the fate
toward either pathology.
MICROGLIA IN GLIOMA
Glioma, the most frequent of primary CNS tumors in adults, are
divided into subtypes by the World Health Organization (WHO).
While the low grade astrocytoma (grade I or II) are treatable
when diagnosed early, high-grade glioma like Glioblastoma
(grade IV) have a median survival limited to∼15 months (Stupp
et al., 2005). To date, it remains unclear how or why this type of
cancer is initiated. The classification of different grades of glioma
has allowed a better understanding on the different genetic
actors involved in the progression of the disease. The mutation
status of the isocitrate dehydrogenase (IDH) gene and the
amplification of platelet-derived growth factor receptor (PDGFR)
and epidermal growth factor receptor (EGFR) is of importance
in the diagnosis and prognosis of glioma (Verhaak et al., 2010;
Leu et al., 2013; The Cancer Genome Atlas Research Network,
2015). Additionally, the status of the deletion 1p/19q will
differentiate grade I from grade II tumors (Leeper et al., 2015).
New tumor microenvironment-derived subtypes of GBM (Wang
et al., 2017) and new markers related to epigenetic changes, such
as the promoter methylation status of the DNA repair enzyme,
O6-methylguanine-DNA-methyltransferase (MGMT), have been
added to the pool of known markers of the glioma progression
(Reifenberger et al., 2016). These constant advancements are
helpful tools for the diagnosis of the disease but the treatment
efficiency and options remain limited. Due to the existence of
many different subtypes, we focused on the GBM subtype and
summarized the features of the disease in Figure 1.
In the last decade, research has intensified on deciphering
the complexity of this devastating disease, yet there is no cure
for GBM. The current treatment for glioma is a combination
of chemotherapy using Temozolomide and irradiation after
resection of the tumor. Despite this radical procedure the average
survival increases by 3 months only (Stupp et al., 2005). The
detrimental prognosis of glioma is due to the high aggressiveness
of the disease where recurrence of the tumor after its resection
commonly occurs. Gliomas can use their environment to grow
and invade very quickly the healthy brain. Recent findings
demonstrate the ability of glioma cells to seize control by the
incorporation into the neuronal network of the brain (Venkatesh
et al., 2019). Peripheral microglia are attracted and recruited
inside the tumor core by the secreted factors released from
the tumor cells like CCL2, CSF1, or EGF (Nolte et al., 1997;
Zhang et al., 2012; Pyonteck et al., 2013; Sielska et al., 2013).
These tumoral environment enrolled microglia will turn into pro-
tumoral cells displaying an opposing function to their protective
brain homeostatic role. This is evident by the secretion of factors
involved in extracellular matrix degradation like MMPs or in
angiogenesis like VEGF, EGF, or IL1B (Tsai et al., 1995; Lafuente
et al., 1999; Markovic et al., 2009), which are needed for tumor
growth and the invasion into the healthy tissue.
Even though the study of glioma-associated microglia is
challenging due to the lack of specific microglia markers and
the infiltration of peripheral myeloid cells, a few human and
mouse studies have defined up-regulated markers linked with
microglia/macrophages in the glioma context. Both, CD163
and CD204, identify anti-inflammatory glioma-associated
microglia/macrophages (or GAMs), which are present in higher
glioma grade and consequently leading to worse survival
(Komohara et al., 2008). A recent gene expression meta-analysis
on two different glioma mouse models by Haage et al. (2019)
distinguished microglia from macrophages in the healthy
brain and under glioma conditions. Using publicly available
mouse datasets, the authors identified in line with other studies
(Hickman et al., 2013; Butovsky et al., 2014; Bennett et al., 2016)
P2ry12, Tmem119, Slc2a5, and Fcrls as a set of genes specific to
microglia that will help to differentiate these from macrophages
as has been validated in RCAS and GL261 glioma mouse
models (Haage et al., 2019). This study confirmed previous data
obtained by Bowman et al. (2016) where, using lineage tracing
mouse models, they observe that macrophages and microglia
would acquire specific transcriptional networks through a
tumor-mediated education.
MICROGLIA IN AD
Alzheimer’s disease is the most common neurodegenerative
disease with a higher prevalence in women (Figure 1) and
clinically defined by the gradual decline in memory and
other cognitive functions. Regionally, AD begins in the medial
temporal lobes and progresses in a caudal–rostral manner to
the frontal lobe (Figure 1). Pathologically, it is characterized by
neuroinflammation, extensive neuronal loss, and the progressive
accumulation and deposition of insoluble amyloid β (Aβ) plaques
in the brain. Plaques have long been considered as a causal
effect to AD initiation, yet this hypothesis is under debate
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FIGURE 1 | Comparison of distinct features for Glioblastoma and AD reveals contrasting pathologies and involvement of microglia.
(De Strooper and Karran, 2016). The amyloid hypothesis was
fueled by the identification of a dominant inherited genomic
alteration in three genes resulting in imbalanced processing and
subsequent aggregation of Aβ. Mutations in APP, PSEN2, and
PSEN2 as well as the triplication of the APP gene contribute to 5–
10% of early onset familial forms of AD. However, familial early
onset AD is extremely rare and maybe an atypical form of the
disease, representing 1–2% of all cases (Campion et al., 1999).
Aging and genetic components are the two main risk factors
for AD with the vast majority of patients displaying AD
symptoms from 65 years of age with an average survival time
of 8.3 years from diagnosis (Figure 1; Alzheimer’s Association,
2019). Although this late onset AD (LOAD) involves a strong
genetic predisposition, no single model can explain the mode
of disease transmission. To date, more than 30 gene loci have
been implicated in LOAD with the APOE gene being the major
risk factor (Corder et al., 1993). Several other low-risk loci have
been implicated in LOAD including TREM2, CLU, PICALM,
CR1, BIN1, MS4A gene cluster, CD2AP, CD33, EPHA1, and
ABCA7 (Harold et al., 2009; Lambert et al., 2009; Hollingworth
et al., 2011; Naj et al., 2011; Kunkle et al., 2019). Risk variants
of AD that are associated with microglia of the aged brain
(Figure 1) are TREM2, CD33, INPP5D, HLA-DQA1, MS4A4A,
CASS1, SORL1, SCIMP, SPPL2A, APOC1, and ATXN7L (Olah
et al., 2018), which makes microglia a central player in recent
AD research. Although it is currently not clear how microglia
contribute to the disease, various studies point toward inefficient
microglial phagocytosis of Aβ plaques and lipid processing
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(Shi and Holtzman, 2018) as at least one of the main contributors.
Microglia are associated with plaques in murine AD models, as
well as in AD patients. Current understanding of the role of these
plaque-associated microglia indicates that they form a barrier
surrounding amyloid deposits, limiting their outward expansion
(Yuan et al., 2018).
SUPPORTING EVIDENCE FOR THE
INVERSE RELATION BETWEEN AD AND
CANCER
Almost three decades ago the first two reports emerged on a
negative association regarding the occurrence of cancer of various
tissue origin and AD in the same individual (Tirumalasetti
et al., 1991; DeSouky, 1992). Both letters state that patients
diagnosed with AD did not have cancer or undergone cancer
treatment at the time of the investigation. Vice versa, cancer
patients are less likely to develop AD. Since then a small number
of longitudinal studies were conducted all of which reinforce
these observations (Yamada et al., 1999; Roe et al., 2005, 2010;
Driver et al., 2012; Musicco et al., 2013; Ou et al., 2013). Two
independent lines of research revealed that patients with a history
of cancer had a reduced risk of developing AD by 33–40%,
while dementia patients demonstrated a reduced risk of 56–
70% for future cancer (Roe et al., 2010; Driver et al., 2012).
Additionally, the quantity of cancer (>1) has shown to lower the
chances of AD (Nudelman et al., 2014). Most interestingly, this
inverse relationship was greatly affected by the type of dementia.
While reportedly vascular dementia demonstrated no significant
association to cancer, the likelihood to develop cancer was the
lowest in patients with pure or probable AD (Roe et al., 2010;
Driver et al., 2012). One of the common risk factors for both
diseases is age, which has been taken into consideration by two
independent studies. The research conducted in Taiwan reported
that especially female patients diagnosed with AD between 60
and 79 years of age had a reduced risk for cancer (Ou et al.,
2013). Musicco et al. (2013) revealed a greater decrease on cancer
risk in AD patients of both genders from 65 years onward,
which is in line with the average begin of diagnosis of AD
(Alzheimer’s Association, 2019). In contrast, this study comprised
of an Italian cohort suggests that the risk remained low with
increasing age to 85+ years (Musicco et al., 2013). The age-
related observation in patients with a cancer history exhibiting
a smaller likelihood to develop AD was made in the same
study. Despite the knowledge that the type of dementia can play
a role in the described effect here, nearly all studies applied
data of cancer overall and largely not distinguishing between
different types of cancer. This is due to the high variability
in the prevalence of various cancers. Our interest lies in the
relationship between AD and glioma and more specifically the
role of microglia in this association. The current challenge
is the collection of sufficient and significant information on
the relationship between glioma and AD considering the low
incidence rate of primary brain tumors such as GBM (∼2–
3 in 100,000).
MICROGLIA ASSOCIATED GENES AND
PATHWAYS AS POSSIBLE PLAYERS IN
DISEASE FATE
The underlying mechanism and/or genetic predisposition that
support the pathology of one but not the other disease has
been speculated (Behrens et al., 2009; Liu T. et al., 2013; Snyder
et al., 2017), yet the question what initiates the fate toward
either condition remains. What came first? Glioma or AD and
what specific role could microglia play in this correlation? In
the absence of disease, age-related changes of the microglia
transcriptome are apparent as early as middle-age and regionally
distinct. Particularly, changes in sensing and engaging with their
local environment correlate with the regional susceptibility to
age-related neurodegenerative diseases (Grabert et al., 2016).
While AD is diagnosed for the majority of cases from 65 years
of age (Alzheimer’s Association, 2019), the development of the
disease and early markers (e.g., CSF, Aβ) has its beginnings
decades before (Jack and Holtzman, 2013; Selkoe and Hardy,
2016). Thus, as AD progresses over years prior to the clinical
diagnosis the local environment may be pushed in one direction
and thereby restrain the development of glioma. In contrast, the
prevalence of glioma increases drastically at the age of 45 years
(Ferris et al., 2017). Cells (e.g., microglia) of cancer survivors
may have acquired a distinct phenotype throughout the disease
and treatment which prevents the development of AD. Here we
describe a small number of selected genes and pathway related to
microglia in either disease, which we think could be of interest for
future investigations and application.
TREM2 is a cell surface receptor highly expressed in microglia.
It recognizes multiple components including apoptotic cells,
apolipoproteins (e.g., APOE and CLU), Aβ oligomers (Zhao et al.,
2018), and endogenous ligands such as galectin-3 (Boza-Serrano
et al., 2019). Activation of TREM2 leads to the sequestration
of DAP12 leading to microglial proliferation, survival, and
phagocytosis (reviewed by Shi and Holtzman, 2018). Notably,
APOE, CLU, and DAP12 are identified as AD risk genes
(Figure 1). The role of TREM2 in AD has been the subject of
intense research. TREM2 expression is upregulated in microglia
with the progression of the disease, when microglia feature
an enhanced phagocytotic profile (Keren-Shaul et al., 2017).
TREM2-deficient microglia show reduced Aβ uptake in vitro
(Yeh et al., 2016), in vivo (Wang Y. et al., 2016; Yuan et al.,
2018), as well as reduced aggregation and proliferation around
plaques (Jay et al., 2015; Wang et al., 2015). On the other
hand, a recent study reported that TREM2 is significantly
upregulated in glioma tissue and is associated with glioma
progression (Wang X.-Q. et al., 2016). Further studies to elucidate
the role of TREM2 in AD and glioma and its relation to
microglia are needed.
APOE is a lipid carrier regulating lipid homeostasis and also
acts as a ligand for TREM2, regulating the TREM2-mediated
microglia phagocytosis (Yeh et al., 2016). There are three
common human APOE alleles, ε2, ε3, and ε4, which differ by
two amino acids. APOE allele ε4 is the major known genetic risk
factor for AD; it is estimated that 40% of people diagnosed with
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AD have this allele (Liu C.-C. et al., 2013). In contrast, APOE ε3
appears not to have a correlation with AD, while APOE ε2 has
been shown to infer a protective role (Yeh et al., 2016). If APOE
should have a role in glioma, it has not yet been revealed.
Neuropillin-1 (or NRP1), a transmembrane receptor
expressed by various cells in the body, plays a role in brain
tumor progression through its expression in microglia. Indeed,
Miyauchi et al. (2016, 2018) demonstrated that the deletion of
NRP1 in microglia leads to the reduction of glioma progression
in vivo and its expression in microglial cells is correlated with
poor prognosis in high grade gliomas (Caponegro et al., 2018).
The function of NRP1 in AD is poorly studied with only one
study hinting toward NRP1 as potential marker of inflammatory
microglia in AD based on the proteomics analysis of microglial
plasma membranes after treatment with a synthetic Aβ peptide
(Correani et al., 2017).
Our group uncovered the non-apoptotic role of Caspase-
3 (CASP3) in the phenotype polarization of microglia. The
stimulation of microglia cells by inflammogens will lead to
the activation of CASP3 without cell death induction in vitro
or in vivo. In turn, active CASP3 promotes, through a
PKCδ-dependent pathway, the pro-inflammatory activation of
microglia. This microglial CASP3 activation has been observed
in the frontal cortex of AD patients which confirms a role
for CASP3 in AD (Burguillos et al., 2011). In contrast, the
activation of microglia into a pro-tumoral phenotype under
glioma conditions is associated with a decrease of the basal
level of CASP3 in microglia by the glioma cells (Shen et al.,
2016). These opposite roles of CASP3 in the different microglial
phenotypes acquisition between AD and glioma could be an
explanation of the inverse correlation of the two pathologies and
the role microglia could play in the fate of the brain (for review
see Shen et al., 2017, 2018).
A few studies have highlighted the phosphoinositide 3 kinase –
Akt – mammalian target of rapamycin (PI3k-Akt-mTor, PAM)
pathway (Liu T. et al., 2013; Majd et al., 2019) as a possible
common mechanism that may be the link in the inverse relation
between AD and cancer in general. Thus, proteins upstream or
downstream of this pathway could exert influence. Interestingly,
some of the example genes described here can partly be linked
with PAM underlining a potentially critical role in the decision
process for either disease. In case of TREM2, upon ligand binding
(e.g., APOE) and interacting with DAP12 as adapter protein
the PI3K cascade is activated leading to cellular proliferation,
survival, and phagocytosis (Konishi and Kiyama, 2018). With
regards to AD, this mechanism is thought to support highly
energetic microglia in order to cluster around Aβ plaques (Zhou
et al., 2018). Yet it could be identified that the microglial cells
of AD patients with a confirmed deficiency in TREM2 trigger
the enhancement of mTOR-regulated autophagy for survival
(Ulland et al., 2018).
In conclusion, these few examples demonstrate the current
lack of information in the interplay of microglia-associated genes
and pathways toward either pathology. Less than a handful
of genes are well described to be active in AD (e.g., CASP3)
but decrease in glioma; or upregulated in glioma and being a
risk variant in AD leading to gene deficiency (e.g., TREM2).
Yet, some genes could be both up- or downregulated in either
disease due to the effect of aging. CLEC7A (C-type lectin domain
containing 7a, also known as DECTIN-1) is one example. This
anti-microbial pattern recognition receptor (Goodridge et al.,
2011) is increasingly expressed by microglia with age (Holtman
et al., 2015; Raj et al., 2017). Moreover, the expression of Clec7a
in mouse models of neurodegeneration (e.g., multiple sclerosis,
amyotrophic lateral sclerosis, AD) (Olah et al., 2012; Keren-Shaul
et al., 2017; Krasemann et al., 2018) and glioma (Szulzewsky
et al., 2015) was upregulated and has recently included as a
marker for disease-associated microglia (DAM) (Keren-Shaul
et al., 2017). Thus, it is necessary to extend the scope of future
research for which we provide a number of suggestions in the
subsequent section.
PROPOSED GUIDELINES FOR FUTURE
RESEARCH AND DIAGNOSTICS
To uncover and understand the microglial and mechanistic
contribution to the inverse relation of AD and glioma, future
research faces a number of challenges, which once overcome
can lead to new tools in diagnostics and ultimately alternative
treatment opportunities. In Figure 2, we summarized our
suggestions for future studies in a form of potential guidelines
that could be followed either in research investigations or in a
clinical setting.
The majority of longitudinal studies examined the relation
between cancer and AD on a broad scale largely unable to
concentrate on the association of AD with a distinct type
of cancer. Certainly, the analysis into the relation of glioma
with AD will take a considerable number of years due to
the low frequency occurrence of glioma. A large-scale study
stretching over a significant period of time would further allow
the distinction between men and women (Figure 2) as has
been reported that women are more likely to develop AD
than cancer, while this is the opposite for men. Moreover,
the evidence regarding the differences of microglia based on
gender is increasing (Guneykaya et al., 2018; Villa et al., 2018)
underlining the importance of distinction. One issue of previous
and possibly future studies will be the misdiagnosis of glioma
for AD and vice versa (Figure 2) as initial pathology with the
performance of minimal test to establish correct diagnosis as
likely reason. Furthermore, once a patient is diagnosed with
either disease no additional examination is being performed
to exclude the possibility of the other. Thus, either disease
may remain undetected and therefore is not being reported
(Figure 2). Future work, although laborious and costly, would
profoundly benefit from extended examination to underline
present findings. Simple tools such as diagnostic marker would
facilitate this procedure.
The use of microglial markers that are expressed in one
pathology and not the other will be of great benefit for the
diagnosis at early stages of the diseases. As mentioned previously,
a marker like Caspase-3 or disease-associated risk alleles, which
are expressed differentially in microglia based on the disease
context would be a highly valuable tool to add in the first steps of
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FIGURE 2 | Overview of the current challenges and proposed guidelines for future studies and diagnostic tools.
the patients’ clinical investigation. The challenge to identify genes
or proteins that could be applied in the clinical setting is due to
the high percentage of studies focusing on few of many microglia-
associated risk genes in AD in great detail (e.g., TREM2, APOE).
Simultaneously, identified AD risk genes are not or weakly
studied in a different disease setting such as glioma. Considering
the remarkable inverse relationship of these pathologies it could
be worth to investigate distinct risk genes greatly associated with
one disease regarding their nature in the other. There is an
obvious need to identify other potential microglial targets useful
for diagnostics which could be done by developing a larger scale
study including AD and glioma patients.
In summary, there is very little knowledge and evidence how
microglia may contribute toward the fate of these two opposing
pathologies. More than a decade ago, Schwartz et al. (2006)
reviewed the idea whether stimulated microglia may be set for
a distinct phenotype or if there is the possibility to reverse an
induced functional phenotype. It was concluded that based on
the type of the primary and secondary trigger, microglia are
capable either to reverse or exaggerate their commitment. It
is then possible to consider that once activated in a specific
disease context, microglia would maintain this acquired disease
phenotype (e.g., AD) and could be unable to go back to another
state, excluding the apparition of another disease such as glioma.
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